Abstract
Primary chronic venous disease (CVD) is a common condition that can cause significant morbidity for sufferers and considerable burden on health care systems. Prolonged venous hypertension in conjunction with valvular incompetence and venous reflux is responsible for the diverse clinical manifestations of CVD and links all theories regarding CVD pathogenesis. Recent data suggest that valve damage may be acquired rather than congenital, and caused by inflammatory factors, notably leukocyte activation triggered by venous hypertension. Valve incompetence leads to reflux, reinforcing venous pressure elevation and initiating a vicious circle of disease progression. Loss of venous tone and lymphatic overload also play a role. Valve failure in superficial and perforating veins leads to elevated pressure in the veins and venules of the skin and subcutaneous tissue, resulting in skin hyperpigmentation, induration and ultimately ulceration. The inflammatory cascade may be ameliorated by pharmacologic intervention to decrease leukocyte activation and leukocyte endothelial interactions at both macro- and microcirculatory levels. Daflon 500 mg (micronized purified flavonoid fraction) offers great potential for achieving this with demonstrated efficacy in reducing inflammation and thus providing tissue protection at all stages of the disease. Experiments in animal and human models of CVD have shown that Daflon 500 mg modulates leukocyte rolling and adhesion and prevents endothelial damage in both veins and capillaries. Such treatment is useful for first-line management of edema as well as associated symptoms of CVD. A recent meta-analysis has confirmed that venous leg ulcer healing is accelerated by adding Daflon 500 mg to conventional treatment.
Keywords: Chronic venous disease, micronized purified flavonoid fraction, venous hypertension, venous reflux
Current Pharmaceutical Design
Title: Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Volume: 13 Issue: 4
Author(s): Luigi Pascarella
Affiliation:
Keywords: Chronic venous disease, micronized purified flavonoid fraction, venous hypertension, venous reflux
Abstract: Primary chronic venous disease (CVD) is a common condition that can cause significant morbidity for sufferers and considerable burden on health care systems. Prolonged venous hypertension in conjunction with valvular incompetence and venous reflux is responsible for the diverse clinical manifestations of CVD and links all theories regarding CVD pathogenesis. Recent data suggest that valve damage may be acquired rather than congenital, and caused by inflammatory factors, notably leukocyte activation triggered by venous hypertension. Valve incompetence leads to reflux, reinforcing venous pressure elevation and initiating a vicious circle of disease progression. Loss of venous tone and lymphatic overload also play a role. Valve failure in superficial and perforating veins leads to elevated pressure in the veins and venules of the skin and subcutaneous tissue, resulting in skin hyperpigmentation, induration and ultimately ulceration. The inflammatory cascade may be ameliorated by pharmacologic intervention to decrease leukocyte activation and leukocyte endothelial interactions at both macro- and microcirculatory levels. Daflon 500 mg (micronized purified flavonoid fraction) offers great potential for achieving this with demonstrated efficacy in reducing inflammation and thus providing tissue protection at all stages of the disease. Experiments in animal and human models of CVD have shown that Daflon 500 mg modulates leukocyte rolling and adhesion and prevents endothelial damage in both veins and capillaries. Such treatment is useful for first-line management of edema as well as associated symptoms of CVD. A recent meta-analysis has confirmed that venous leg ulcer healing is accelerated by adding Daflon 500 mg to conventional treatment.
Export Options
About this article
Cite this article as:
Pascarella Luigi, Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease, Current Pharmaceutical Design 2007; 13 (4) . https://dx.doi.org/10.2174/138161207780162953
DOI https://dx.doi.org/10.2174/138161207780162953 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Therapeutical Perspectives of S-Allylcysteine: Effect on diabetes and other disorders in Animal Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Management of Type 2 Diabetes: More Evidence is Required to Address the Clinical and Contextual Facets
Current Diabetes Reviews Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Physical Disability in Older Adults
Current Aging Science Novel Sample Preparation for Mass Spectral Analysis of Complex Biological Samples
Current Proteomics Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Apolipoprotein E Knockout Models
Current Pharmaceutical Design Targeting Angiogenesis in Thyroid Cancer
Current Angiogenesis (Discontinued) The Role of 11Beta-Hydroxysteroid Dehydrogenase in Metabolic Disease and Therapeutic Potential of 11Beta-HSD1 Inhibitors
Current Medicinal Chemistry Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
Current Pharmaceutical Design Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design Diagnostics and Therapy of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitides
Current Pharmaceutical Design Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds